Metabolic and toxicological considerations for sepsis drug treatments

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 1, 2013, Pages 79-89

  Campbell, Sarah C ^a   Spigarelli, Michael G ^a   Courter, Joshua ^b   Sherwin, Catherine Mt ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Metabolism; Neonatal; Pediatric; Sepsis; Toxicology

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTIINFECTIVE AGENT; CEFTRIAXONE; DOBUTAMINE; DOPAMINE; DOPEXAMINE; GENTAMICIN; NETILMICIN; NORADRENALIN; STREPTOMYCIN; TOBRAMYCIN;

ANTISEPSIS; DRUG ELIMINATION; HUMAN; HYPOTENSION; KIDNEY FUNCTION; LUNG DISEASE; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; NONHUMAN; PERFUSION; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; KIDNEY DISEASES; SEPSIS; TREATMENT OUTCOME;

ANIMALIA;

EID: 84871245118     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.727396     Document Type: Review

References (100)

1. Sepsis. National Health Service, United Kingdom Department of Health. Available from: http://www.nhs.uk/ Conditions/Blood-poisoning/Pages/ Introduction.aspx Updated 4 April 2010 1 May 2012]
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiologyof severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29(7):1303-10 (Pubitemid 32641789)
3. Weycker D, Akhras KS, Edelsberg J, et al. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med 2003;31(9):2316-23 (Pubitemid 37100834)
4. Elixhauser A, Machlin SR, Zodet MW, et al. Health care for children and youth in the United States: 2001 annual report on access, utilization, quality, and expenditures. Ambul Pediatr 2002;2(6):419-37 (Pubitemid 35476800)
5. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101(10):3765-77 (Pubitemid 36857845)
6. Hall MJW, Sonja N, DeFrances Carol J, Golosinskiy Aleksandr MS. NationalCenter for Health Statistics Data Brief, No. 622011; (June). Available from: http://www.cdc.gov/nchs/data/databriefs/ db62.pdf
7. Long SSP, Larry K, Prober CG. editor. Principles and practice of pediatric infectious diseases. 3rd edition. Elsevier, Inc; Philadelphia, PA, USA: 2008
8. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001;29(7 Suppl):S109-16 (Pubitemid 32681592)
9. Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003;167(5):695-701 (Pubitemid 36801744)
10. Witek-Janusek L, Cusack C. Neonatal sepsis: confronting the challenge. Crit Care Nurs Clin North Am 1994;6(2):405-19
11. Fonseca SN, Ehrenkranz RA, Baltimore RS. Epidemiology of antibiotic use in a neonatal intensive care unit. Infect Control Hosp Epidemiol 1994;15(3):156-62
12. Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease.Risk factors, prevention strategies, and vaccine development. Epidemiol Rev 1994;16(2):374-402
13. Ng PC, Cheng SH, Chui KM, et al.Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, andC-reactive protein in preterm very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 1997;77(3):F221-7
14. Chiesa C, Pellegrini G, Panero A, et al. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003;49(1):60-8 (Pubitemid 36078554)
15. Arkader R, Troster EJ, Lopes MR, et al. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child 2006;91(2):117-20 (Pubitemid 43372019)
16. Short MA. Linking the sepsis triad of inflammation, coagulation, and suppressed fibrinolysis to infants. Adv Neonatal Care 2004;4(5):258-73 (Pubitemid 39446349)
17. Carrigan SD, Scott G, Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem 2004;50(8):1301-14 (Pubitemid 38970636)
18. Rubin LG, Sanchez PJ, Siegel J, et al. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices. Pediatrics 2002;110(4):e42
19. Escobar GJ, Zukin T, Usatin MS, et al. Early discontinuation of antibiotic-treatment in newborns admitted to rule out Sepsis - a decision rule. Pediatr Infect Dis J 1994;13(10):860-6 (Pubitemid 24322781)
20. Poschl JMB, Hellstern G, Dertlioglou N, et al. Six day antimicrobial therapy for early-onset group B streptococcal infection in near-term and term neonates. Scand J Infect Dis 2003;35(5):302-5 (Pubitemid 36889322)
21. Nadel S. Severe pediatric sepsis. Expert Rev Anti Infect Ther 2012;10(2):111-14
22. Brilli RJ, Goldstein B. Pediatric sepsis definitions: past, present, and future. Pediatr Crit Care Med 2005;6(3 Suppl):S6-8 (Pubitemid 40724244)
23. Martin GS, Mannino DM, Eaton S,Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348(16):1546-54 (Pubitemid 36437931)
24. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101(6):1481-3
25. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20(6):864-74.
26. Zanotti Cavazzoni SL, Dellinger RP. Hemodynamic optimization of sepsis-induced tissue hypoperfusion. Crit Care 2006;10(Suppl 3):S2
27. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362(9):779-89
28. Myburgh JA, Higgins A, Jovanovska A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008;34(12):2226-34
29. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrineinfusion in patients with septic shock. N Engl J Med 2008;358(9):877-87 (Pubitemid 351397087)
30. Young JD. The heart and circulation insevere sepsis. Br J Anaesth 2004;93(1):114-20
31. Ferreira AM, Sakr Y. Organ dysfunction: general approach, epidemiology, and organ failure scores. Semin Respir Crit Care Med 2011;32(5):543-51
32. Kenney EM, Rozanski EA, Rush JE, et al. Association between outcome and organ system dysfunction in dogs with sepsis: 114 cases (2003-2007). J Am Vet Med Assoc 2010;236(1):83-7
33. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;351(2):159-69
34. Spapen H. Liver perfusion in sepsis, septic shock, and multiorgan failure. Anat Rec (Hoboken) 2008;291(6):714-20
35. van Lambalgen AA, Bronsveld W, van den Bos GC, Thijs LG. Distribution of cardiac output, oxygen consumption and lactate production in canine endotoxin shock. Cardiovasc Res 1984;18(4):195-205 (Pubitemid 14131657)
36. Flournoy DJ, Beller BK, Archer LT, Hinshaw LB. Relationship of serum gentamicin levels and methylprednisolone sodium succinate treatment in baboons challenged with Escherichia coli LD100. Clin Ther 1983;5(4):417-21 (Pubitemid 13059887)
37. Beller BK, Archer LT, Passey RB, et al. Effectiveness of modified steroid-antibiotic therapies for lethal sepsis in the dog. Arch Surg 1983;118(11):1293-9 (Pubitemid 13022381)
38. Hinshaw LB, Beller BK, Chang AC, et al. Evaluation of naloxone for therapy of Escherichia coli shock. Species differences. Arch Surg 1984;119(12):1410-18 (Pubitemid 15215906)
39. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003;112(4):460-7 (Pubitemid 38056327)
40. Perkins MW, Dasta JF, DeHaven B. Physiologic implications of mechanical ventilation on pharmacokinetics. Dicp1989;23(4):316-23 (Pubitemid 19102686)
41. Zhou M, Maitra SR, Wang P. The potential role of transcription factor aryl hydrocarbon receptor in downregulation of hepatic cytochrome P-450 during sepsis. Int J Mol Med2008;21(4):423-8
42. Wu R, Cui X, Dong W, et al. Suppression of hepatocyte CYP1A2 expression by Kupffer cells via AhR pathway: the central role of proinflammatory cytokines. Int J Mol Med 2006;18(2):339-46
43. Lee SH, Lee SM. Suppression of hepatic cytochrome p450-mediated drug metabolism during the late stage of sepsis in rats. Shock 2005;23(2):144-9
44. Crawford JH, Yang S, Zhou M, et al. Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med 2004;32(2):502-8 (Pubitemid 38234132)
45. Higgins MA, Berridge BR, Mills BJ, et al. Gene expression analysis of the acute phase response using a canine microarray. Toxicol Sci 2003;74(2):470-84 (Pubitemid 36958314)
46. Wang P, Ba ZF, Chaudry IH. Mechanism of hepatocellular dysfunction during early sepsis. Key role of increased gene expression and release of proinflammatory cytokines tumor necrosis factor and interleukin-6. Arch Surg 1997;132(4):364-9; discussion 9-70
47. Sharma VK, Dellinger RP. Treatment options for severe sepsis and septic shock. Expert Rev Anti Infect Ther 2006;4(3):395-403 (Pubitemid 43905462)
48. Bonnet F, Richard C, Glaser P, et al. Changes in hepatic flow induced by continuous positive pressure ventilation in critically ill patients. Crit Care Med 1982;10(11):703-5
49. Jardin F, Desfond P, Bazin M, et al. Controlled ventilation with best positive end-expiratory pressure (PEEP) and high level PEEP in acute respiratory failure (ARF). Intensive Care Med 1981;7(4):171-6
50. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002;41(14):1135-51 (Pubitemid 35398690)
51. Siegel JH, Cerra FB, Coleman B, et al.Physiological and metabolic correlations in human sepsis. Surgery 1979;86(2):163-93
52. Routledge PA. Factors contributing to variability in drug pharmacokinetics. Pt 2. Drug distribution. J Clin Hosp Pharm 1985;10(1):15-23 (Pubitemid 15103368)
53. Gill MA, Kern JW. Altered gentamicin distribution in ascitic patients. Am J Hosp Pharm 1979;36(12):1704-6 (Pubitemid 10217877)
54. Pennington JE, Dale DC, Reynolds HY, MacLowry JD. Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis 1975;132(3):270-5
55. Hansen M, Christrup LL, Jarlov JO, et al. Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand 2001;45(6):734-40 (Pubitemid 32613466)
56. Dorman T, Swoboda S, Zarfeshenfard F, et al. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Surgery 1998;124(1):73-8 (Pubitemid 28354688)
57. Oparaoji EC, Cornwell EE, Hekmat E, et al. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm 1993;12:131-4 (Pubitemid 23035005)
58. Fanos V, Dall'Agnola A. Antibiotics in neonatal infections - a review. Drugs 1999;58(3):405-27
59. Bailey RR. Aminoglycosides. Drugs 1981;22:321-7
60. Marik PE. Aminoglycoside Volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993;21(2):172-3 (Pubitemid 23132762)
61. Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002;28(7):936-42
62. Chambers HF. The aminoglycosides. Goodman and Gillman's: the pharmacological basis of therapeutics. McGraw-Hill Professional; New York, USA; 2001
63. Begg EJ, Barclay ML. Aminoglycosides - 50 Years on. Br J Clin Pharmacol 1995;39(6):597-603
64. Lingvall M, Reith DM, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 2005;59(1):54-61 (Pubitemid 40040096)
65. Aperia N, Broberger O, Elinder G, et al. Postnatal development of renal function in pre-term and full-term infants. Acta Paediatr Scand 1981;70:183-7 (Pubitemid 11184380)
66. Gallini F, Maggio L, Romangnoli C,et al. Progression of renal function in preterm neonates with gestational age < 32 weeks. Pediatr Nephrol 2000;15:119-24
67. Cooper K, Bennett WM. Nephrotoxicity of common drugs used in clinical practice. Arch Intern Med 1987;147(7):1213-18 (Pubitemid 17102145)
68. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008;78(6):743-50
69. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984;100(3):352-7 (Pubitemid 14156536)
70. Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988;33(4):900-11
71. Candidiasis (Moniliasis, Thrush) 2009 1 January 2009. Available from: http://aapredbook.aappublications.org
72. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
73. Becker BN, Fall P, Hall C, et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis 1993;22(4):611-15 (Pubitemid 23308976)
74. Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982;73(1A):182-5 (Pubitemid 12067781)
75. Dobie RA, Black FO, Pezsnecker SC, Stallings VL. Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. Arch Otolaryngol Head Neck Surg 2006;132(3):253-7
76. Wadsworth SJ, Suh B. In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns. Antimicrob Agents Chemother 1988;32(10):1571-5
77. Information for Healthcare Professionals: Ceftriaxone (marketed as Rocephin and generics)2010. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation forPatientsandProviders/Drug SafetyInformationforHeathcare Professionals/ucm084263.htm
78. Hodgman T, Dasta JF, Armstrong DK, et al. Ampicillin-associated seizures. South Med J 1984;77(10):1323-5 (Pubitemid 14014450)
79. Shaffer CL, Davey AM, Ransom JL, et al. Ampicillin-induced neurotoxicity in very-low-birth-weight neonates. Ann Pharmacother 1998;32(4):482-4 (Pubitemid 28166617)
80. Ampicillin for Injection, USP. New York, NY, USA; 2010
81. Narasimha A, Harendra Kumar ML. Significance of Hematological Scoring System (HSS) in early diagnosis of neonatal sepsis. Indian J Hematol Blood Transfus 2011;27(1):14-17
82. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164(3):396-402 (Pubitemid 32778205)
83. Luzzani A, Polati E, Dorizzi R, et al. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003;31(6):1737-41 (Pubitemid 36714230)
84. Faix JD. Established and novel biomarkers of sepsis. Biomark Med 2011;5(2):117-30
85. Sherwin C, Broadbent R, Young S, et al. Utility of interleukin-12 and interleukin-10 in comparison with other cytokines and acute-phase reactants in the diagnosis of neonatal sepsis. Am J Perinatol 2008;25(10):629-36
86. Vanlaere I, Libert C. Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock.
87. Clin Microbiol Rev 2009;22(2):224-39; Table of Contents
88. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009;158(3):983-94
89. Wang H, Meng K, Chen W, et al. Serum miR-574-5p: a prognostic predictor of sepsis patients. Shock 2012;37(3):263-7
90. Sauer U, Pultar J, Preininger C. Critical role of the sample matrix in a point-of-care protein chip for sepsis. J Immunol Methods 2012;378(1-2):44-50
91. Suberviola B, Castellanos-Ortega A, Llorca J, et al. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly 2012;142:w13542
92. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005;4(10):854-65 (Pubitemid 41553966)
93. Esmon CT. Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 2004;32(5 Suppl):S219-22
94. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock 1998;9(1):1-11 (Pubitemid 128463868)
95. West MA, Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002;30(1 Supp):S64-73 (Pubitemid 34131164)
96. Chaudry IH. Sepsis: lessons learned in the last century and future directions. Arch Surg 1999;134(9):922-9 (Pubitemid 29428900)
97. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990;49(2):186-96 (Pubitemid 20241651)
98. Wang JE, Dahle MK, McDonald M, et al. Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis: receptors, signal transduction, biological effects, and synergism. Shock 2003;20(5):402-14
99. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003;16(3):379-414 (Pubitemid 36871313)
100. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs